Every material Form 8-K Zura Bio Ltd has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zura Bio said its Phase 2 TibuSHIELD study of tibulizumab in moderate-to-severe hidradenitis suppurativa did not meet its primary endpoint at Week 16 at either dose, and key secondary endpoints were also not met. Based on the results, the company is discontinuing development of tibulizumab in HS, while its systemic sclerosis and polymyalgia rheumatica programs continue. The failure removes one indication from the company's lead product candidate.
Primary endpoint (percentage change from baseline in abscess and inflammatory nodule count) not met: 56.0% reduction at 300 mg and 58.1% at 150 mg, versus 52.5% for placebo
HiSCR50 response was 48.0% (300 mg) and 52.7% (150 mg) versus 45.5% for placebo; HiSCR75 was 35.3% and 34.0% versus 28.1%
Trial enrolled 247 participants; both doses were well tolerated per the company, with one death in the 300 mg arm judged unrelated to treatment by the site investigator
As of September 30, 2026, cash and cash equivalents were $187.7 million, expected to fund operations through at least the end of 2028; TibuSURE topline data expected in H1 2027
Zura Bio reported a third-quarter 2026 net loss of $25.8 million, or $0.20 per share, up from $18.0 million, or $0.21 per share, a year earlier, as research and development and general and administrative spending rose. The company said its $187.7 million in cash and cash equivalents as of September 30, 2026 is expected to fund planned operations through at least the end of 2028, and it reaffirmed timing for topline data from two Phase 2 tibulizumab studies.
Net loss of $25.8 million ($0.20 per share) for Q3 2026, compared with $18.0 million ($0.21 per share) in Q3 2025.
R&D expenses rose to $19.5 million from $11.9 million; G&A expenses rose to $9.3 million from $7.6 million.
Cash and cash equivalents were $187.7 million as of September 30, 2026, with runway expected through at least the end of 2028.
TibuSHIELD topline data in hidradenitis suppurativa remains on track for Q4 2026, TibuSURE data in systemic sclerosis for H1 2027, and NEXUS-PMR is set to start by year-end 2026.
Zura Bio Limited furnished an updated corporate presentation dated August 17, 2026, for use at upcoming conferences and investor meetings, filed as Exhibit 99.1. The filing contains no financial results or guidance; the presentation covers the company's tibulizumab pipeline, including Phase 2 studies in hidradenitis suppurativa and systemic sclerosis, and states a cash runway through at least year end 2028.
Presentation dated August 17, 2026, filed as Exhibit 99.1 and posted at investors.zurabio.com
Topline data from the HS Phase 2 study expected in Q4 2026; the SSc Phase 2 study in H1 2027
Company states cash runway through at least year end 2028
No financial results or guidance included; information is furnished under Item 7.01 and not deemed filed
Zura Bio reported a second-quarter 2026 net loss of $26.3 million, or $0.21 per share, up from $16.0 million, or $0.17 per share, a year earlier. Research and development expenses rose to $20.7 million from $8.7 million, which the company attributed to its Phase 2 tibulizumab programs, and it reported $205.1 million in cash as of June 30, 2026, which it expects to fund planned operations through at least the end of 2028.
Net loss of $26.3 million ($0.21 per share) for Q2 2026, versus $16.0 million ($0.17 per share) in Q2 2025
R&D expenses of $20.7 million versus $8.7 million a year earlier; G&A expenses fell to $8.6 million from $9.4 million
Cash and cash equivalents of $205.1 million as of June 30, 2026, with runway through at least the end of 2028
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zura Bio Ltd filing is on SEC EDGAR ↗. 8-K briefs of other companies →